Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials. (2024). SKIN The Journal of Cutaneous Medicine, 8(1), s305. https://doi.org/10.25251/skin.8.supp.305